Seeking Alpha

Zogenix takes it on the chin due to looming competitive threat

Comments (7)
  • pj4272
    , contributor
    Comments (28) | Send Message
     
    How about that favorable (to ZGNX) court ruling in the afternoon?

     

    http://bit.ly/1jbU43F
    8 Jul 2014, 04:05 PM Reply Like
  • John Kastanes
    , contributor
    Comments (1216) | Send Message
     
    Can you paste the information please?
    8 Jul 2014, 04:50 PM Reply Like
  • ScottyGreen
    , contributor
    Comments (110) | Send Message
     
    just click the link and then click the document over to the right, done.
    8 Jul 2014, 04:58 PM Reply Like
  • pj4272
    , contributor
    Comments (28) | Send Message
     
    Judge wrote:

     

    "With these principles in mind, I conclude as follows:

     

    Plaintiff has stated a plausible claim for relief. Defendants’ motion to dismiss is denied without prejudice.

     

    Plaintiff’s motion to preliminarily enjoin the “LMN regulation,” 243 CMR2.07(25)(d) and 263 CMR 5.07(12)(d), is allowed. If defendants provide adequate and constitutional guidance to physicians regarding the prerequisites for prescribing Zohydro in compliance with the regulation, then they may thereafter move to lift the injunction.

     

    Because its sealed declaration does not provide sufficient detail that pharmacies will not carry Zohydro, plaintiff has not met its burden of proofon the “pharmacist-only regulation,” 247 CMR 8.05(3). Its motion for a preliminary injunction is denied without prejudice to renewal upon a moredetailed submission."

     

    http://bit.ly/1tkrAsP
    8 Jul 2014, 05:00 PM Reply Like
  • Charlieboy Stevens
    , contributor
    Comments (85) | Send Message
     
    With its many millions of dollars, ZGNX has the capability to bring a great medical product to market which, with the related patent protection, has a potentially great future, which could include a multiple point rise in the value of its stock. I only own publicly traded stocks developing one or more medical products, each one of which ha patent and or other protection's. So says Charlieboy.
    8 Jul 2014, 04:38 PM Reply Like
  • ScottyGreen
    , contributor
    Comments (110) | Send Message
     
    AND, Purdue (whopper 120mg pill) may not even GET approval.
    Remember when zohydro came out and media was saying "it could kill a baby" etc, what do you think they would say about this? ADT or not, it's more than twice as strong as zohydro HIGHEST potency pill! The FDA isn't going to approve something just because it HAS ADT with all of the heat that has surrounded this circus. Big pharma started all of this smear campaign, and it's going to come back and bite them HARD.
    8 Jul 2014, 04:50 PM Reply Like
  • followsgartman
    , contributor
    Comments (22) | Send Message
     
    Wow, the bulls come out swinging. Let us get real and discard the hyperbole. Zogenix is a Penney stock and the company is going to need to replenish its capital at year-end. No one can predict the future in respect to the FDA’s response to their October NDA, will there be sufficient safety characteristics built into their initial deterrence technology? From my perception, I anticipate opioid’s have about a two-four year relevancy, because the backlash and negative costs surrounding opioids are significant. I understand they failed to fill fourteen sales positions, and they dropped two additional underperforming territories. The rumor is approximately fifty sales positions will be cut, and I see this as a positive rather than a negative, especially significant when compared to how management wasted investor’s capital in the past associated to “Sumavel Dose Pro” (a niche, within a niche market product). The company and the bulls appear to find themselves caught up in the hype, unable to see the forest through the trees based on cognitive dissidence.

     

    However, the fact remains in the world of opioids this is one of many “go-to” options and likely the most dangerous option of the bunch that are already approved. It is expensive, its risks outweigh its benefits, and even the carefully crafted results in trials are unimpressive, when a placebo can essentially compete with the drug on many levels. I am unconvinced. The only thing Zogenix has going for them is that many significant investors are stuck and they are reluctant to dump, which would collapse the share price to about $1.00. Thus, the large investors are sticking around impatiently waiting for a window of opportunity to open where some will jump ship. Moreover, a stock like this really affects the books, which is not at all desirable.

     

    My belief is the safer way to play this stock like an option, there will be excellent opportunities to capitalize on its dips and swings. The company is nothing more than a small-cap irrelevant stock in a huge market reserved for the tried, proven, and tested. It has a very small chance to become relevant with other bigger and better players entering the market against the backlash that surround opioids that will not disappear anytime soon. You have to recognize, without discarding the fact that the United States represents almost ninety-five percent of the entire opioid market, thus, you have to ask yourself how do pain patients in other parts of the world survive without free unfettered access to opioids?

     

    This is an unnacceptable reality, the negative affects surrounding opioid missuse (and in this category I could provide pages and pages of negatives) are also negatively affecting our deficit and ultimately our economic survival. Look at the situation rationally, and you will not be placing yourself in a high-risk situation with minimal opportunity for meaningful gains in share price over the medium or long-term.
    9 Jul 2014, 02:44 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs